🇺🇸 FDA
Patent

US 11098025

Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

granted A61KA61K45/06A61P

Quick answer

US patent 11098025 (Bi-functional compounds and methods for targeted ubiquitination of androgen receptor) held by Montelino Therapeutics Inc. expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Montelino Therapeutics Inc.
Grant date
Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K45/06, A61P, A61P13/08, A61P35/00